Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Patients with severe aortic stenosis accepted for transcatheter intervention or open surgery are included before the intervention, and then followed up with clinical visits during the first year after intervention. Imaging with echocardiography and computed tomography (CT) are performed together with additional imaging with magnetic resonance imaging (MRI) and Positron emissions tomography (PET)-CT in a subgroup of the study population. Blood samples, physical performance and questionnaires with focus on frailty and heart failure are also collected at each visit. A follow up with information of the outcomes after 2-5 years will be performed through national registries.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Preserved heart function | The group will be defined as preserved left ventricular ejection fraction (LVEF) with and without hypertrophy and with and without reduced global longitudinal strain (GLS). |
| |
| Reduced heart function | The group will be defined as reduced LVEF |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| There is no intervention since it is an observational study patients are treated according to clinical praxis | Other | No intervention |
|
| Measure | Description | Time Frame |
|---|---|---|
| Semiquantitative assessment of protein levels associated with myocardial performance | Level of normalized protein expression (NPX) in plasma, assessed by a multiplex proximity extension assay panel (Olink Bioscience, Uppsala, Sweden). | One year after intervention. |
| Imaging parameters associated with clinical outcome after intervention | Global longitudinal strain (%) of the right and left ventricle. The clinical outcome defined as a combination of mortality and hospitalization of heart failure | One year after intervention |
| Semiquantitative assessment of protein levels associated with myocardial performance associated with clinical outcome after intervention | Level of normalized protein expression (NPX) in plasma, assessed by a multiplex proximity extension assay panel (Olink Bioscience, Uppsala, Sweden). The clinical outcome defined as a combination of mortality and hospitalization for heart failure. | Two years after intervention |
| Measure | Description | Time Frame |
|---|---|---|
| Imaging parameters associated with clinical outcome after intervention | Volumes of the right and left ventricle (mL/m2). The clinical outcome defined as a combination of mortality and hospitalization for heart failure. | Two years after intervention |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
All patients accepted for aortic valve intervention due to aortic stenosis
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Christina Christersson, MD PhD | Contact | +46186119068 | christina.christersson@medsci.uu.se |
| Name | Affiliation | Role |
|---|---|---|
| Christina Christersson, MD PhD | VO hjärt-lungmedicin och klinisk fysiologi Akademiska Sjukhuset | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of cardiology Uppsala University Hospital | Recruiting | Uppsala | 75185 | Sweden |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001024 | Aortic Valve Stenosis |
| ID | Term |
|---|---|
| D000082862 | Aortic Valve Disease |
| D006349 | Heart Valve Diseases |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood samples
| D014694 |
| Ventricular Outflow Obstruction |